[ad_1] Results from the 8,179-subject REDUCE-IT study evaluation Amarin's (NASDAQ: AMRN) Vascepa (icosapent ethyl) in statin-treated adults with elevated cardiovascular (CV) risk showed a significant treatment effect. The data were presented at …
Read More »
[ad_1] In the United States, smoking is declining and researchers have quantified the benefits of quitting for health. However, new research from American Heart Association revealed that it takes over 15 years …
Read More »
[ad_1] Taking medication for high blood pressure does not provide any benefit to patients with mild hypertension in terms of reducing the risk of death or cardiovascular disease, although they present a …
Read More »
[ad_1] Seoul, South Korea (UroToday.com) Ajay Nehra MD summarized the leading causes of death among men, including cardiovascular diseases, and the most common and deadly cancers among men. Cardiovascular disease is the …
Read More »
[ad_1] Thanks to the pleasure of SCOTUS, we had a lot of heart failure moments last week, so let's talk about something good for your heart! I am a big skeptic of …
Read More »
[ad_1] The biopharmaceutical company Amarin is doing the history of heart medicine Monday with its patented formulation of fish oil, called Vascepa. In a breathtaking clinical trial result that challenges years of …
Read More »
[ad_1] The biopharmaceutical company Amarin is doing the history of heart medicine Monday with its patented formulation of fish oil, called Vascepa. In a breathtaking clinical trial result that challenges years of …
Read More »
[ad_1] A A heart health survey revealed that this week, four out of five adults in England had a more damaged heart than their age. England's "cardiac age test", taken by two …
Read More »